Patents by Inventor William C. Fanslow, III

William C. Fanslow, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytokine which is a ligand for OX40
    Patent number: 5783665
    Abstract: There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: July 21, 1998
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, William C. Fanslow, III, Richard B. Gayle, Raymond G. Goodwin
  • Method of preventing or treating disease characterized by neoplastic cells expressing CD40
    Patent number: 5674492
    Abstract: There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: October 7, 1997
    Assignees: Immunex Corporation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard J. Armitage, William C. Fanslow, III, Dan L. Longo, William J. Murphy
  • Detection of mutations in a CD40 ligand gene
    Patent number: 5565321
    Abstract: There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating a syndrome that results in elevated levels of serum IgM and diminished levels of all other isotypes of immunoglobulins are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: October 15, 1996
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III
  • Cytokine which is a ligand for OX40
    Patent number: 5457035
    Abstract: There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: October 10, 1995
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, William C. Fanslow, III, Richard B. Gayle, Raymond G. Goodwin